Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 3/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.42 |
| ▸ | BRS3 | P32247 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19567209 | 0.82 | SMN1; SMN2 (0.56) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL1020541 | 0.82 | LMNA (0.49) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL6869977 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL696687 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL179126 | 0.81 | CYP1A2 (0.58) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL6847934 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL13109196 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL676381 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL4573341 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL5013994 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008077651-A1 | PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-03 | — | — | WO | claimed |
| EP-4069697-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20230065034-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-4069697-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| WO-2021113263-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| CN-103694244-B | 3,6 replace-1,2,4-triazole also [3,4-a] Phthalazines and preparation thereof and purposes | ZHENGZHOU UNIVERSITY (CN) | 2016-03-30 | — | — | CN | disclosed |
| US-8729089-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| EP-2252299-B1 | FUSED PYRIDONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2014-03-19 | — | — | EP | disclosed |
| US-20080242666-A1 | 1-6-Substituted (3R,6R)-3-(2,3-Dihydro-1H-Inden-2-Yl)-2,5-Piperazinedione Derivatives as Oxytocin Receptor Antagonists For the Treatment of Preterm Labour, Dysmenorrhea and Endometriosis | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| US-20080242666-A1 | 1-6-Substituted (3R,6R)-3-(2,3-Dihydro-1H-Inden-2-Yl)-2,5-Piperazinedione Derivatives as Oxytocin Receptor Antagonists For the Treatment of Preterm Labour, Dysmenorrhea and Endometriosis | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| US-20080242666-A1 | 1-6-Substituted (3R,6R)-3-(2,3-Dihydro-1H-Inden-2-Yl)-2,5-Piperazinedione Derivatives as Oxytocin Receptor Antagonists For the Treatment of Preterm Labour, Dysmenorrhea and Endometriosis | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| WO-2008077651-A1 | PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065034-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | CRHR1, CRH, CRHR2 | SMN1; SMN2 2724/4885KDM4E 4829/4885ALDH1A1 2173/4885 |
| US-20080242666-A1 | 1-6-Substituted (3R,6R)-3-(2,3-Dihydro-1H-Inden-2-Yl)-2,5-Piperazinedione Derivatives as Oxytocin Receptor Antagonists For the Treatment of Preterm Labour, Dysmenorrhea and Endometriosis | OXTR, OPRL1, GPER1 | SMN1; SMN2 2103/4885KDM4E 2691/4885ALDH1A1 642/4885 |
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, DPYD, PNP | SMN1; SMN2 2183/4885KDM4E 3976/4885ALDH1A1 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.